← Back to home

BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE)

Clinical trials for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE) explained in plain language.

Never miss a new study

Get alerted when new BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE) trials appear

Sign up with your email to follow new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Not yet finished but already full! 2

New bladder treatment aims to stop Cancer's return, spare patients major surgery

Disease control Not yet recruiting

This Phase 3 study is testing a new drug called NDV-01 for people with non-muscle invasive bladder cancer (NMIBC). It aims to see if putting the drug directly into the bladder can prevent the cancer from coming back and stop it from getting worse, which could help patients avoid …

Matched conditions: BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE)

Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE)

Get alerted when new BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE) trials appear

New bladder treatment aims to stop Cancer's return, spare patients major surgery